Context Therapeutics (NASDAQ:CNTX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Context Therapeutics (NASDAQ:CNTX) released its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03, FiscalAI reports.

Context Therapeutics Stock Down 1.2%

Shares of CNTX stock traded down $0.03 during trading on Wednesday, reaching $2.41. 506,317 shares of the company’s stock were exchanged, compared to its average volume of 977,034. The stock has a market capitalization of $221.43 million, a PE ratio of -6.34 and a beta of 1.57. Context Therapeutics has a twelve month low of $0.49 and a twelve month high of $3.62. The firm’s fifty day moving average price is $2.63 and its 200-day moving average price is $1.90.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Context Therapeutics by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after acquiring an additional 134,449 shares during the last quarter. Millennium Management LLC acquired a new position in Context Therapeutics in the 4th quarter valued at $3,824,000. Marshall Wace LLP grew its holdings in Context Therapeutics by 7,153.7% in the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after buying an additional 2,557,448 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Context Therapeutics by 58.8% in the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after buying an additional 188,202 shares in the last quarter. Finally, State Street Corp grew its holdings in Context Therapeutics by 8.5% in the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after buying an additional 13,000 shares in the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on CNTX. Wall Street Zen cut Context Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Lifesci Capital upgraded Context Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. Guggenheim restated a “buy” rating and issued a $5.00 target price on shares of Context Therapeutics in a research note on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Monday, April 20th. Finally, Piper Sandler boosted their price target on Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Context Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $6.60.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.